Search

Your search keyword '"Usmani, Saad Z"' showing total 1,449 results
Start Over Author "Usmani, Saad Z"
1,449 results on '"Usmani, Saad Z"'

151. Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Author

Martin, Thomas, primary, Usmani, Saad Z., additional, Berdeja, Jesus G., additional, Agha, Mounzer, additional, Cohen, Adam D., additional, Hari, Parameswaran, additional, Avigan, David, additional, Deol, Abhinav, additional, Htut, Myo, additional, Lesokhin, Alexander, additional, Munshi, Nikhil C., additional, O'Donnell, Elizabeth, additional, Stewart, A. Keith, additional, Schecter, Jordan M., additional, Goldberg, Jenna D., additional, Jackson, Carolyn C., additional, Yeh, Tzu-Min, additional, Banerjee, Arnob, additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Olyslager, Yunsi, additional, Zhou, Changwei, additional, Pacaud, Lida, additional, Madduri, Deepu, additional, Jakubowiak, Andrzej, additional, Lin, Yi, additional, and Jagannath, Sundar, additional

Published
2023
Full Text
View/download PDF

152. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Author

Van Oekelen, Oliver, primary, Nath, Karthik, additional, Mouhieddine, Tarek H., additional, Farzana, Tasmin, additional, Aleman, Adolfo, additional, Melnekoff, David T., additional, Ghodke-Puranik, Yogita, additional, Shah, Gunjan L., additional, Lesokhin, Alexander, additional, Giralt, Sergio, additional, Thibaud, Santiago, additional, Rossi, Adriana, additional, Rodriguez, Cesar, additional, Sanchez, Larysa, additional, Richter, Joshua, additional, Richard, Shambavi, additional, Cho, Hearn J., additional, Chari, Ajai, additional, Usmani, Saad Z., additional, Jagannath, Sundar, additional, Shah, Urvi A., additional, Mailankody, Sham, additional, and Parekh, Samir, additional

Published
2023
Full Text
View/download PDF

153. A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Author

Paul, Barry, primary, Liedtke, Michaela, additional, Khouri, Jack, additional, Rifkin, Robert, additional, Gandhi, Mitul D, additional, Kin, Andrew, additional, Levy, Moshe Y, additional, Silbermann, Rebecca, additional, Cottini, Francesca, additional, Sborov, Douglas W, additional, Sandhu, Irwindeep, additional, Villarreal, Lyssa, additional, Murphy, Michael, additional, Gu, Lin, additional, Chen, Ann, additional, Rajakumaraswamy, Nishanthan, additional, and Usmani, Saad Z, additional

Published
2023
Full Text
View/download PDF

154. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Author

Diamond, Benjamin T., primary, Ziccheddu, Bachisio, additional, Maclachlan, Kylee H., additional, Taylor, Justin, additional, Boyle, Eileen Mary, additional, Arango Ossa, Juan Esteban, additional, Jahn, Thomas Jacob, additional, Affer, Maurizio, additional, Totiger, Tulasigeri M., additional, Coffey, David G, additional, Chandhok, Namrata, additional, Watts, Justin M, additional, Cimmino, Luisa, additional, Lu, Sydney X, additional, Bolli, Niccolo, additional, Bolton, Kelly L, additional, Landau, Heather J., additional, Park, Jae H., additional, Ganesh, Karuna, additional, McPherson, Andrew, additional, Sekeres, Mikkael A., additional, Lesokhin, Alexander M, additional, Chung, David J., additional, Zhang, Yanming, additional, Ho, Caleb, additional, Roshal, Mikhail, additional, Tyner, Jeffrey W, additional, Nimer, Stephen D, additional, Papaemmanuil, Elli, additional, Usmani, Saad Z., additional, Morgan, Gareth J, additional, Landgren, Ola, additional, and Maura, Francesco, additional

Published
2023
Full Text
View/download PDF

155. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study

Author

Dhakal, Binod, primary, Zhang, Mei-Jei, additional, Burns, Linda J., additional, Tang, Xiaoying, additional, Meyer, Christa, additional, Mau, Lih-Wen, additional, Nooka, Ajay K., additional, Stadtmauer, Edward, additional, Micallef, Ivana N, additional, McGuirk, Joseph, additional, Costa, Luciano, additional, Juckett, Mark B., additional, Shah, Nina, additional, Champlin, Richard E., additional, Usmani, Saad Z., additional, Farag, Sherif S., additional, Nishihori, Taiga, additional, Roy, Vivek, additional, Bodiford, Andrew, additional, Barnes, Yvonne J., additional, Drea, Edward J., additional, Hari, Parameswaran, additional, and Hamadani, Mehdi, additional

Published
2023
Full Text
View/download PDF

156. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Author

Nahi, Hareth, primary, Usmani, Saad Z., additional, Mateos, Maria-Victoria, additional, van de Donk, Niels W. C. J., additional, Oriol, Albert, additional, Plesner, Torben, additional, Bandyopadhyay, Nibedita, additional, Hellemans, Peter, additional, Tromp, Brenda, additional, Nnane, Ivo, additional, Zemlickis, Donna, additional, Chari, Ajai, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

161. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Author

Kumar, Shaji, Paiva, Bruno, Anderson, Kenneth C, Durie, Brian, Landgren, Ola, Moreau, Philippe, Munshi, Nikhil, Lonial, Sagar, Bladé, Joan, Mateos, Maria-Victoria, Dimopoulos, Meletios, Kastritis, Efstathios, Boccadoro, Mario, Orlowski, Robert, Goldschmidt, Hartmut, Spencer, Andrew, Hou, Jian, Chng, Wee Joo, Usmani, Saad Z, Zamagni, Elena, Shimizu, Kazuyuki, Jagannath, Sundar, Johnsen, Hans E, Terpos, Evangelos, Reiman, Anthony, Kyle, Robert A, Sonneveld, Pieter, Richardson, Paul G, McCarthy, Philip, Ludwig, Heinz, Chen, Wenming, Cavo, Michele, Harousseau, Jean-Luc, Lentzsch, Suzanne, Hillengass, Jens, Palumbo, Antonio, Orfao, Alberto, Rajkumar, S Vincent, Miguel, Jesus San, and Avet-Loiseau, Herve

Published
2016
Full Text
View/download PDF

163. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Author

Lonial, Sagar, Weiss, Brendan M, Usmani, Saad Z, Singhal, Seema, Chari, Ajai, Bahlis, Nizar J, Belch, Andrew, Krishnan, Amrita, Vescio, Robert A, Mateos, Maria Victoria, Mazumder, Amitabha, Orlowski, Robert Z, Sutherland, Heather J, Bladé, Joan, Scott, Emma C, Oriol, Albert, Berdeja, Jesus, Gharibo, Mecide, Stevens, Don A, LeBlanc, Richard, Sebag, Michael, Callander, Natalie, Jakubowiak, Andrzej, White, Darrell, de la Rubia, Javier, Richardson, Paul G, Lisby, Steen, Feng, Huaibao, Uhlar, Clarissa M, Khan, Imran, Ahmadi, Tahamtan, and Voorhees, Peter M

Published
2016
Full Text
View/download PDF

164. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors

Author

Klyuchnikov, Evgeny, Bacher, Ulrike, Kröger, Nicolaus M., Hari, Parameswaran N., Ahn, Kwang Woo, Carreras, Jeanette, Bachanova, Veronika, Bashey, Asad, Cohen, Jonathon B., D'Souza, Anita, Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, Hertzberg, Mark S., Holmberg, Leona A., Kharfan-Dabaja, Mohamed A., Klein, Andreas, Ku, Grace H., Laport, Ginna G., Lazarus, Hillard M., Miller, Alan M., Mussetti, Alberto, Olsson, Richard F., Slavin, Shimon, Usmani, Saad Z., Vij, Ravi, Wood, William A., Maloney, David G., Sureda, Anna M., Smith, Sonali M., and Hamadani, Mehdi

Published
2015
Full Text
View/download PDF

165. Bone marrow Ki‐67 index is of prognostic value in newly diagnosed multiple myeloma.

Author

Atrash, Shebli, Robinson, Myra, Taneja, Alankrita, Paul, Barry, Cassetta, Kristen, Ndiaye, Ami, Varga, Cindy, Block, Jared, Lipford, Edward H., Smith, Elton T., McCall, Chad M., Thurston, Virginia, Foureau, David, Usmani, Saad Z., Voorhees, Peter M., and Bhutani, Manisha

Subjects
BONE marrow, MULTIPLE myeloma, KI-67 antigen, PROGNOSIS, PROGRESSION-free survival, PLASMACYTOMA
Abstract

Background: Ki‐67 is an index of proliferative activity and is an established predictive and prognostic marker in multiple malignancies. However, its prognostic relevance in multiple myeloma (MM) is unclear. We investigated the relationship between Ki‐67 expression and survival outcomes in MM in the era of novel therapies. Methods: We interrogated our database to identify patients with MM, newly diagnosed between July 1, 2013 and December 31, 2020, with Ki‐67 expression assessed by immunohistochemistry (IHC) on bone marrow biopsies. Using an established threshold of 5% we defined Ki‐67low (≤5%) and Ki‐67high (>5%) subgroups for association with progression‐free survival (PFS) and overall survival (OS). Results: Of 167 patients included: 53 (31.7%) had Ki‐67high and 114 had Ki‐67low. More patients with R‐ISS 3 had Ki‐67high (22.2% vs. 9.7%). The gain of 1q21 was overrepresented in the Ki‐67high group (28% vs. 8%). Median PFS in the Ki‐67low group was 3.1 years, and in the Ki‐67high group 1.6 years (log‐rank p <.001, HR: 1.9). Median OS was not reached in the Ki‐67low vs. 4.8 years in the Ki‐67high cohort (HR: 1.9; log‐rank test: p =.018). In the multivariable modeling, after adjusting for other risk factors, HR for Ki‐67high versus Ki‐67low was 2.4 (p <.001) for PFS and 2.1 (p =.026) for OS. Conclusions: Our results demonstrate that a high Ki‐67 index (>5%) is an independent prognostic marker associated with worse OS and PFS in newly diagnosed MM. IHC staining for Ki‐67 on bone marrow biopsies could be easily adopted as a prognostic biomarker for MM in economically constrained healthcare settings. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

168. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials

Author

Chhabra, Saurabh, primary, Callander, Natalie, additional, Watts, Nicole L., additional, Costa, Luciano J., additional, Thapa, Bicky, additional, Kaufman, Jonathan L., additional, Laubach, Jacob, additional, Sborov, Douglas W., additional, Reeves, Brandi, additional, Rodriguez, Cesar, additional, Chari, Ajai, additional, Silbermann, Rebecca, additional, Anderson, Larry D., additional, Bal, Susan, additional, Dhakal, Binod, additional, Nathwani, Nitya, additional, Shah, Nina, additional, Medvedova, Eva, additional, Bumma, Naresh, additional, Holstein, Sarah A., additional, Costello, Caitlin, additional, Jakubowiak, Andrzej, additional, Wildes, Tanya M., additional, Schmidt, Timothy, additional, Orlowski, Robert Z., additional, Shain, Kenneth H., additional, Cowan, Andrew J., additional, Dholaria, Bhagirathbhai, additional, Cornell, R. Frank, additional, Jerkins, James H., additional, Pei, Huiling, additional, Cortoos, Annelore, additional, Patel, Sharmila, additional, Lin, Thomas S., additional, Usmani, Saad Z., additional, Richardson, Paul G., additional, and Voorhees, Peter M., additional

Published
2022
Full Text
View/download PDF

169. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Author

Martin, Tom, primary, Usmani, Saad Z., additional, Schecter, Jordan M., additional, Roccia, Tito, additional, Jackson, Carolyn C., additional, Deraedt, William, additional, Yeh, Tzu-min, additional, Banerjee, Arnob, additional, Pacaud, Lida, additional, Garrett, Ashraf, additional, Bartlett, Meaghan, additional, Haltner, Anja, additional, Van Sanden, Suzy, additional, Diels, Joris, additional, Valluri, Satish, additional, and Samjoo, Imtiaz A., additional

Published
2022
Full Text
View/download PDF

170. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Author

Sklavenitis-Pistofidis, Romanos, primary, Aranha, Michelle P., additional, Redd, Robert A., additional, Baginska, Joanna, additional, Haradhvala, Nicholas J., additional, Hallisey, Margaret, additional, Dutta, Ankit K., additional, Savell, Alexandra, additional, Varmeh, Shohreh, additional, Heilpern-Mallory, Daniel, additional, Ujwary, Sylvia, additional, Zavidij, Oksana, additional, Aguet, Francois, additional, Su, Nang K., additional, Lightbody, Elizabeth D., additional, Bustoros, Mark, additional, Tahri, Sabrin, additional, Mouhieddine, Tarek H., additional, Wu, Ting, additional, Flechon, Lea, additional, Anand, Shankara, additional, Rosenblatt, Jacalyn M., additional, Zonder, Jeffrey, additional, Vredenburgh, James J., additional, Boruchov, Adam, additional, Bhutani, Manisha, additional, Usmani, Saad Z., additional, Matous, Jeffrey, additional, Yee, Andrew J., additional, Jakubowiak, Andrzej, additional, Laubach, Jacob, additional, Manier, Salomon, additional, Nadeem, Omar, additional, Richardson, Paul, additional, Badros, Ashraf Z., additional, Mateos, Maria-Victoria, additional, Trippa, Lorenzo, additional, Getz, Gad, additional, and Ghobrial, Irene M., additional

Published
2022
Full Text
View/download PDF

171. A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

Author

Nath, Karthik, primary, Shekarkhand, Tala, additional, Salcedo, Meghan, additional, Derkach, Andriy, additional, Rueda, Siobhan, additional, Chansakul, Aisara, additional, Hulcrantz, Malin, additional, Korde, Neha, additional, Shah, Urvi A., additional, Tan, Carlyn, additional, Chung, David J., additional, Lahoud, Oscar B., additional, Hassoun, Hani, additional, Lesokhin, Alexander M., additional, Landau, Heather J., additional, Shah, Gunjan, additional, Scordo, Michael, additional, Giralt, Sergio A., additional, Usmani, Saad Z., additional, Roshal, Mikhail, additional, Landgren, Ola, additional, and Mailankody, Sham, additional

Published
2022
Full Text
View/download PDF

172. Poster: MM-181 CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Usmani, Saad Z, primary, Martin, Thomas, additional, Berdeja, Jesus G, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D, additional, Deol, Abhinav, additional, Htut, Myo, additional, Lesokhin, Alexander, additional, Munshi, Nikhil C, additional, O'Donnell, Elizabeth, additional, Jackson, Carolyn C, additional, Yeh, Tzu-min, additional, Banerjee, Arnob, additional, Zudaire, Enrique, additional, Madduri, Deepu, additional, Zhou, Changwei, additional, Pacaud, Lida, additional, Lin, Yi, additional, and Jagannath, Sundar, additional

Published
2022
Full Text
View/download PDF

175. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Author

Rajkumar, S Vincent, Dimopoulos, Meletios A, Palumbo, Antonio, Blade, Joan, Merlini, Giampaolo, Mateos, María-Victoria, Kumar, Shaji, Hillengass, Jens, Kastritis, Efstathios, Richardson, Paul, Landgren, Ola, Paiva, Bruno, Dispenzieri, Angela, Weiss, Brendan, LeLeu, Xavier, Zweegman, Sonja, Lonial, Sagar, Rosinol, Laura, Zamagni, Elena, Jagannath, Sundar, Sezer, Orhan, Kristinsson, Sigurdur Y, Caers, Jo, Usmani, Saad Z, Lahuerta, Juan José, Johnsen, Hans Erik, Beksac, Meral, Cavo, Michele, Goldschmidt, Hartmut, Terpos, Evangelos, Kyle, Robert A, Anderson, Kenneth C, Durie, Brian G M, and Miguel, Jesus F San

Published
2014
Full Text
View/download PDF

176. GPRC5D-Targeted CAR T Cells for Myeloma

Author

Mailankody, Sham, primary, Devlin, Sean M., additional, Landa, Jonathan, additional, Nath, Karthik, additional, Diamonte, Claudia, additional, Carstens, Elizabeth J., additional, Russo, Douglas, additional, Auclair, Romany, additional, Fitzgerald, Lisa, additional, Cadzin, Briana, additional, Wang, Xiuyan, additional, Sikder, Devanjan, additional, Senechal, Brigitte, additional, Bermudez, Vladimir P., additional, Purdon, Terence J., additional, Hosszu, Kinga, additional, McAvoy, Devin P., additional, Farzana, Tasmin, additional, Mead, Elena, additional, Wilcox, Jessica A., additional, Santomasso, Bianca D., additional, Shah, Gunjan L., additional, Shah, Urvi A., additional, Korde, Neha, additional, Lesokhin, Alexander, additional, Tan, Carlyn R., additional, Hultcrantz, Malin, additional, Hassoun, Hani, additional, Roshal, Mikhail, additional, Sen, Filiz, additional, Dogan, Ahmet, additional, Landgren, Ola, additional, Giralt, Sergio A., additional, Park, Jae H., additional, Usmani, Saad Z., additional, Rivière, Isabelle, additional, Brentjens, Renier J., additional, and Smith, Eric L., additional

Published
2022
Full Text
View/download PDF

177. Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

Author

Costa, Luciano J., primary, Hari, Parameswaran, additional, Berdeja, Jesus G., additional, De Stefano, Valerio, additional, Gay, Francesca, additional, Hooper, Becky, additional, Bartlett, Meaghan, additional, Haltner, Anja, additional, Rosta, Emily, additional, Kumar, Shaji, additional, Martin, Thomas, additional, Mateos, Maria-Victoria, additional, Moreau, Philippe, additional, Usmani, Saad Z., additional, Olyslager, Yunsi, additional, Schecter, Jordan M., additional, Roccia, Tito, additional, Garrett, Ashraf, additional, Lee, Sam, additional, Nesheiwat, Tonia, additional, Pacaud, Lida, additional, Zhou, Changwei, additional, Samjoo, Imtiaz A., additional, Lin, Yi, additional, Diels, Joris, additional, Valluri, Satish, additional, and Weisel, Katja, additional

Published
2022
Full Text
View/download PDF

184. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Author

Davies, Faith E., primary, Pawlyn, Charlotte, additional, Usmani, Saad Z., additional, San-Miguel, Jesus F., additional, Einsele, Hermann, additional, Boyle, Eileen M., additional, Corre, Jill, additional, Auclair, Daniel, additional, Cho, Hearn Jay, additional, Lonial, Sagar, additional, Sonneveld, Pieter, additional, Stewart, A. Keith, additional, Bergsagel, P. Leif, additional, Kaiser, Martin F., additional, Weisel, Katja, additional, Keats, Jonathan J., additional, Mikhael, Joseph R., additional, Morgan, Kathryn E., additional, Ghobrial, Irene M., additional, Orlowski, Robert Z., additional, Landgren, C. Ola, additional, Gay, Francesca, additional, Caers, Joseph, additional, Chng, Wee Joo, additional, Chari, Ajai, additional, Walker, Brian A., additional, Kumar, Shaji K., additional, Costa, Luciano J., additional, Anderson, Kenneth C., additional, and Morgan, Gareth J., additional

Published
2022
Full Text
View/download PDF

185. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Author

Stuver, Robert, primary, Shah, Gunjan L., additional, Korde, Neha S., additional, Roeker, Lindsey E., additional, Mato, Anthony R., additional, Batlevi, Connie L., additional, Chung, David J., additional, Doddi, Sital, additional, Falchi, Lorenzo, additional, Gyurkocza, Boglarka, additional, Hamilton, Audrey, additional, Lin, Ya-Hui, additional, Jakubowski, Ann A., additional, Joffe, Erel, additional, Landau, Heather L., additional, Lin, Richard J., additional, Mailankody, Sham, additional, Palomba, M. Lia, additional, Park, Jae H., additional, Perales, Miguel-Angel, additional, Ponce, Doris M., additional, Ramanathan, Lakshmi V., additional, Salles, Gilles A., additional, Scordo, Michael, additional, Seo, Susan K., additional, Shah, Urvi A., additional, Stein, Eytan M., additional, Straus, David, additional, Usmani, Saad Z., additional, Young, James W., additional, Zelenetz, Andrew D., additional, Noy, Ariela, additional, and Vardhana, Santosha A., additional

Published
2022
Full Text
View/download PDF

186. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

Author

Landgren, Ola, primary, Weisel, Katja, additional, Rosinol, Laura, additional, Touzeau, Cyrille, additional, Turgut, Mehmet, additional, Hajek, Roman, additional, Mollee, Peter, additional, Kim, Jin Seok, additional, Shu, Natalie, additional, Hu, Xuguang, additional, Li, Chuang, additional, and Usmani, Saad Z., additional

Published
2022
Full Text
View/download PDF

187. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience

Author

Mohan, Meera, primary, Becnel, Melody Renee, additional, Shah, Urvi A., additional, Dong, Huaying, additional, Gundarlapalli, Sravani, additional, Peterson, Timothy, additional, Orozco, Jennifer S., additional, Horowitz, Sandra, additional, Chhabra, Saurabh, additional, Dhakal, Binod, additional, Thanendrarajan, Sharmilan, additional, Radhakrishnan, Sabarinath Venniyil, additional, Al Hadidi, Samer, additional, Tan, Carlyn, additional, Mailankody, Sham, additional, Hultcrantz, Malin, additional, Korde, Neha, additional, Hassoun, Hani, additional, Lesokhin, Alexander M., additional, Thomas, Sheeba K., additional, Patel, Krina K., additional, Manasanch, Elisabet E., additional, Weber, Donna M., additional, Szabo, Aniko, additional, Kaufman, Gregory P., additional, Lee, Hans C., additional, Zangari, Maurizio, additional, van Rhee, Frits, additional, Usmani, Saad Z., additional, D'Souza, Anita, additional, Orlowski, Robert Z., additional, and Schinke, Carolina, additional

Published
2022
Full Text
View/download PDF

188. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma

Author

Jakubowiak, Andrzej J, primary, Kumar, Shaji, additional, Medhekar, Rohan, additional, Pei, Huiling, additional, Lefebvre, Patrick, additional, Kaila, Shuchita, additional, He, Jianming, additional, Lafeuille, Marie-Hélène, additional, Cortoos, Annelore, additional, Londhe, Anil, additional, Mavros, Panagiotis, additional, Lin, Thomas S, additional, and Usmani, Saad Z, additional

Published
2022
Full Text
View/download PDF

189. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

Author

Martin, Tom, Usmani, Saad Z., Schecter, Jordan M., Roccia, Tito, Jackson, Carolyn C., Deraedt, William, Yeh, Tzu-min, Banerjee, Arnob, Pacaud, Lida, Garrett, Ashraf, Bartlett, Meaghan, Haltner, Anja, Van Sanden, Suzy, Diels, Joris, Valluri, Satish, and Samjoo, Imtiaz A.

Subjects
*MULTIPLE myeloma, *TREATMENT effectiveness, *MONOCLONAL antibodies, *DEEP brain stimulation, *PROGRESSION-free survival, *PROTEASOME inhibitors, *ODDS ratio, *BRAIN stimulation
Abstract

This study used the latest available data cuts from the CARTITUDE-1 and KarMMa clinical trials to update previously published matching-adjusted indirect treatment comparisons (MAICs) assessing the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the FDA-approved idecabtagene vicleucel (ide-cel) dose range of 300 to 450 × 106 CAR-positive T-cells in the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.e. triple-class exposed). MAICs were performed with the latest available individual patient data for cilta-cel (CARTITUDE-1) and published summary-level data for ide-cel (KarMMa). The analyses included treated patients from CARTITUDE-1 who satisfied the eligibility criteria for KarMMa. The MAIC adjusted for unbalanced baseline covariates of prognostic significance identified in the literature and by clinical expertise. Comparative efficacy was assessed for overall response rate (ORR), complete response or better (≥CR) rate, duration of response (DoR), progression-free survival (PFS), and overall survival (OS). Cilta-cel was associated with statistically significantly improved ORR (odds ratio [OR]: 94.93 [95% confidence interval [CI]: 21.86, 412.25; p <.0001]; relative risk [RR]: 1.34), ≥CR rate (OR: 5.65 [95% CI: 2.51, 12.69; p <.0001]; RR: 2.23), DoR (hazard ratio [HR]: 0.52 [95% CI: 0.30, 0.88; p =.0152]), PFS, (HR: 0.38 [95% CI: 0.24, 0.62; p <.0001]), and OS (HR: 0.43 [95% CI: 0.22, 0.88; p =.0200]) compared with ide-cel. These analyses demonstrate improved efficacy with cilta-cel versus ide-cel for all outcomes over longer follow-up and highlight its therapeutic potential in triple-class exposed RRMM patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

191. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

Author

Usmani, Saad Z., primary, Nahi, Hareth, additional, Legiec, Wojciech, additional, Grosicki, Sebastian, additional, Vorobyev, Vladimir, additional, Spicka, Ivan, additional, Hungria, Vania, additional, Korenkova, Sibirina, additional, Bahlis, Nizar J., additional, Flogegard, Max, additional, Bladé, Joan, additional, Moreau, Philippe, additional, Kaiser, Martin, additional, Iida, Shinsuke, additional, Laubach, Jacob, additional, Magen, Hila, additional, Cavo, Michele, additional, Hulin, Cyrille, additional, White, Darrell, additional, De Stefano, Valerio, additional, Lantz, Kristen, additional, O’Rourke, Lisa, additional, Heuck, Christoph, additional, Delioukina, Maria, additional, Qin, Xiang, additional, Nnane, Ivo, additional, Qi, Ming, additional, and Mateos, Maria-Victoria, additional

Published
2022
Full Text
View/download PDF

193. Results from a Meta-Analysis of Ciltacabtagene Autoleucel Compared to Physician’s Choice in Patients with Relapsed or Refractory Multiple Myeloma

Author

Hari, Parameswaran, primary, Berdeja, Jesus G., additional, De Stefano, Valerio, additional, Gay, Francesca, additional, Hooper, Becky, additional, Haltner, Anja, additional, Kumar, Shaji, additional, Martin, Thomas, additional, Mateos, Maria-Victoria, additional, Moreau, Philippe, additional, Rosta, Emily, additional, Samjoo, Imtiaz A., additional, Usmani, Saad Z., additional, Weisel, Katja, additional, Jackson, Carolyn C., additional, Olyslager, Yunsi, additional, Schecter, Jordan M, additional, Vogel, Martin, additional, Garrett, Ashraf, additional, Lee, Sam, additional, Nesheiwat, Tonia, additional, Pacaud, Lida, additional, Zhou, Changwei, additional, Valluri, Satish, additional, Costa, Luciano J., additional, and Lin, Yi, additional

Published
2022
Full Text
View/download PDF

194. Cartitude-5: A Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Intended for Transplant

Author

Agha, Mounzer, primary, Dhakal, Binod, additional, Dytfeld, Dominik, additional, Manier, Salomon, additional, Delforge, Michel, additional, Kuppens, Steven, additional, Afifi, Salma, additional, Deraedt, William, additional, Taraseviciute-Morris, Agne, additional, Schecter, Jordan M, additional, Gilbert, Jane, additional, Yalniz, Fevzi, additional, Florendo, Erika, additional, Pacaud, Lida, additional, Hungria, Vania, additional, Usmani, Saad Z., additional, and Mateos, Maria-Victoria, additional

Published
2022
Full Text
View/download PDF

196. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Author

San-Miguel, Jesus, primary, Avet-Loiseau, Hervé, additional, Paiva, Bruno, additional, Kumar, Shaji, additional, Dimopoulos, Meletios A., additional, Facon, Thierry, additional, Mateos, María-Victoria, additional, Touzeau, Cyrille, additional, Jakubowiak, Andrzej, additional, Usmani, Saad Z., additional, Cook, Gordon, additional, Cavo, Michele, additional, Quach, Hang, additional, Ukropec, Jon, additional, Ramaswami, Priya, additional, Pei, Huiling, additional, Qi, Mia, additional, Sun, Steven, additional, Wang, Jianping, additional, Krevvata, Maria, additional, DeAngelis, Nikki, additional, Heuck, Christoph, additional, Van Rampelbergh, Rian, additional, Kudva, Anupa, additional, Kobos, Rachel, additional, Qi, Ming, additional, and Bahlis, Nizar J., additional

Published
2022
Full Text
View/download PDF

197. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Author

Facon, Thierry, primary, Cook, Gordon, additional, Usmani, Saad Z., additional, Hulin, Cyrille, additional, Kumar, Shaji, additional, Plesner, Torben, additional, Touzeau, Cyrille, additional, Bahlis, Nizar J., additional, Basu, Supratik, additional, Nahi, Hareth, additional, Goldschmidt, Hartmut, additional, Quach, Hang, additional, Mohty, Mohamad, additional, Venner, Christopher P., additional, Weisel, Katja, additional, Raje, Noopur, additional, Hebraud, Benjamin, additional, Belhadj-Merzoug, Karim, additional, Benboubker, Lotfi, additional, Decaux, Olivier, additional, Manier, Salomon, additional, Caillot, Denis, additional, Ukropec, Jon, additional, Pei, Huiling, additional, Van Rampelbergh, Rian, additional, Uhlar, Clarissa M., additional, Kobos, Rachel, additional, and Zweegman, Sonja, additional

Published
2022
Full Text
View/download PDF

198. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

Author

Usmani, Saad Z, primary, Quach, Hang, additional, Mateos, Maria-Victoria, additional, Landgren, Ola, additional, Leleu, Xavier, additional, Siegel, David, additional, Weisel, Katja, additional, Gavriatopoulou, Maria, additional, Oriol, Albert, additional, Rabin, Neil, additional, Nooka, Ajay, additional, Qi, Ming, additional, Beksac, Meral, additional, Jakubowiak, Andrzej, additional, Ding, Bifeng, additional, Zahlten-Kumeli, Anita, additional, Yusuf, Akeem, additional, and Dimopoulos, Meletios, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results